Extensive sequence and structural evolution of Arginase 2 inhibitory antibodies enabled by an unbiased approach to affinity maturation
Denice T. Y. Chan(AstraZeneca (United Kingdom)), Maria Groves(AstraZeneca (United Kingdom)), Lesley Jenkinson(AstraZeneca (United Kingdom)), Yoko Shibata(Fukushima Medical University), Stephanie Ryman(AstraZeneca (United Kingdom)), Mark Austin(John Innes Centre), Jessica Whitehouse(AstraZeneca (United Kingdom)), Mark D. Carr(University of Leicester), Sarah V. Holt(Pharma Nord (United Kingdom)), Stuart W. Haynes(AstraZeneca (United Kingdom)), Robert W. Wilkinson(Immunocore (United Kingdom)), Tristan J. Vaughan(AstraZeneca (United Kingdom)), Michelle Barnard(North-West University), C. Seewooruthun(University of Leicester), Louise H. Slater(AstraZeneca (United Kingdom)), A. Addyman(AstraZeneca (United Kingdom)), Ellen Gowans(AstraZeneca (United Kingdom)), Sebastian Fiedler(AstraZeneca (United Kingdom)), Vincenzo Cerundolo(John Radcliffe Hospital), Agata Diamandakis(AstraZeneca (United Kingdom)), D. Burschowsky(University of Leicester)
Cited by 10
Related Papers
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections
|Nature Medicine|2002|1.6k
Classification of current anticancer immunotherapies
|Oncotarget|2014|469
Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses
|Proceedings of the National Academy of Sciences|2000|398
The crystal structure of human CD1d with and without α-galactosylceramide
|Nature Immunology|2005|389